Skip to main content
Premium Trial:

Request an Annual Quote

Kleinert Brings Pharma Experience to Protometrix

Premium

After 15 years of working in big pharma — on both the commercial and R&D sides at Abbott Laboratories and most recently as global VP of oncology, metabolic, and cardiovascular commercial franchises at Searle-Monsanto — Hollis Kleinert, the new CEO of Protometrix, had very specific requirements for her next “adventure.”

“I was looking for a great technology, with wonderful people to work with,” says Kleinert, who moved to the Guilford, Conn., protein-chip company from Chicago.

She views her diverse background in the pharmaceutical industry as a significant asset to Protometrix. “It is the integration of the science to seamlessly work with the commercial, to plan together and execute together, that really makes you successful and gives you a competitive edge,” Kleinert says. “That is what I want to do right from the beginning in this organization.”

Protometrix has several technologies that help it perform high-throughput protein cloning, expression, and purification; build microarrays based on the 3D structure of the proteins and study protein function under different conditions; and create a software infomatics program to manage the data. The technologies were invented by Yale scientist Michael Snyder.

Since taking over as president and CEO, Kleinert says, “Things have been going great. Better than expected.” The 20-person-and-growing company hopes to have its first product, the yeast biochip, “characterized” by the end of the year, she says. The eventual goal is to produce a human biochip.

— Dana Frisch

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.